Cesca Therapeutics announces commercial launch of its AXP II blood system

red blood cells
Cesca Therapeutics announces the commercial launch of its AXP II blood system.

Cesca Therapeutics, which specializes in regenerative medicine and offers a range of automated technologies for cell-based therapeutics, has announced the commercial launch of its AXP II system.

The AXP II, which was developed by Cesca’s device division ThermoGenesis, is designed to collect, isolate and store hematopoietic stem cell concentrates from cord blood and peripheral blood.

“Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry,” Chris Xu, Cesca’s chief executive, said in a statement. “With AXP II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK software that together represent the biggest advancement in automated cord blood processing in many years.”

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

The company, which went public late last year, acquired SynGen in a deal announced in July that gave Cesca SynGen’s cell processing platform technology. 

Suggested Articles

The FDA’s warning letters to breast implant manufacturers come during newly galvanized agency probes into the long-term safety of silicone implants.

A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.

After a limited launch of its automated glucose monitoring system, OptiScan has raised $20 million for a broader rollout.